Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …

Alzheimer's disease (AD) is a frequent and disabling neurodegenerative disorder, in which
astrocytes participate in several pathophysiological processes including neuroinflammation …

Background The inflammation and oxidative stress (OS) have been considered crucial
components of the pathogenesis of depression. Edaravone (EDA), a free radical scavenger …

Background Alzheimer's disease (AD) is the most common type of neurodegenerative
disease in the contemporary era, and it is still clinically incurable. Eriodictyol, a natural …

Alzheimer's disease (AD) is one of the most common types of age-related dementia
worldwide. In addition to extracellular amyloid plaques and intracellular neurofibrillary …

Accumulating evidence shows that oxidative stress is involved in a wide variety of human
diseases: rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, cancers, etc. Here …

The accumulation of aggregated amyloid-β (Aβ) in the brain is the first critical step in the
pathogenesis of Alzheimer's disease (AD), which also includes synaptic impairment …

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, and it is
characterised by progressive deterioration in cognitive and memory abilities, which can …

Almost 47 million people suffer from dementia worldwide, with an estimated new case
diagnosed every 3.2 seconds. Alzheimer's disease (AD) accounts for approximately 60 …

Alzheimer's disease is a neurodegenerative disorder mainly characterized by β-amyloid
deposit and tau hyperphosphorylation with no curative treatments. Curcumin (Cur) has been …